Download this press release (155 KB).
ROSEVILLE, MN (September 06, 2016) — Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference, to be held September 9, 2016 at the Millennium Broadway Hotel & Conference Center in New York City.
During the presentation, Lee Jones, co-founder, president and CEO, will discuss Rebiotix’s corporate growth strategy and its position as the most clinically advanced microbiome company in the industry. Topics in the presentation will include a review of Rebiotix’s pioneering Microbiota Restoration Therapy (MRT) platform and its drug development pipeline which is led by RBX2660, the company’s Phase 3-ready drug candidate for recurrent Clostridium difficile infection.
Event: BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference
Date: Friday, September 9, 2016
Time: 2:00-2:20 p.m. (Eastern Time)
Location: Millennium Broadway Hotel & Conference Center - Room 508
About Rebiotix Inc.
Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having successfully completed a Phase 2b randomized, double-blind, placebo-controlled trial as a potential treatment for recurrent Clostridium difficile infection (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA. Rebiotix’s development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Amy Wheeler
Tiberend Strategic Advisors
646-362-5750
awheeler@nulltiberend.com